MARATTO

review · Discover Bacteria.

Molecular mechanisms and genetic epidemiology of colistin resistance in Pseudomonas aeruginosa: a systematic review and meta-analysis

20262 citationsOpen access

Abstract

Colistin is a last-resort antibiotic for multidrug-resistant (MDR) and extensively drug-resistant (XDR) P. aeruginosa infections; however, colistin-resistance is rising globally. This study synthesizes global data on colistin-resistance mechanisms, high-risk clones (HRCs), and One Health dynamics. This study screened 1318 records and analyzed 40 studies using PRISMA guidelines. The literature search was conducted from March 01 and April 30, 2025. Data extraction covered colistin-resistance genes, sequence types (STs), and co-resistance patterns. The results reveal that colistin resistance is primarily driven by chromosomal mutations (in pmrAB and phoPQ) and plasmid-borne mcr genes with high detection of mcr-1. HRCs were dominant globally, and most colistin-resistant isolates exhibited co-resistance to β-lactams/carbapenems, amplifying MDR/XDR threats. Resistance rates showed regional heterogeneity in Asia, Europe, and America compared to Africa and the Middle East. The study suggests that regulated colistin use, enhanced genomic surveillance, regular antibiotic stewardship programs, development of rapid diagnostics and novel therapies are necessary to combat the spread of MDR/XDR P. aeruginosa strains.

Research topics

  • Antibiotic Resistance in Bacteria
  • Antibiotic Use and Resistance
  • Antibiotics Pharmacokinetics and Efficacy

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1007/s44351-026-00044-y

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.